These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35641679)

  • 1. Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease.
    Richardson N; Wootton GE; Bozward AG; Oo YH
    Semin Immunopathol; 2022 Jul; 44(4):461-474. PubMed ID: 35641679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T-cell deficiency leads to features of autoimmune liver disease overlap syndrome in scurfy mice.
    Yilmaz K; Haeberle S; Kim YO; Fritzler MJ; Weng SY; Goeppert B; Raker VK; Steinbrink K; Schuppan D; Enk A; Hadaschik EN
    Front Immunol; 2023; 14():1253649. PubMed ID: 37818371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biliary features in liver histology of children with autoimmune liver disease.
    Di Giorgio A; D'Adda A; Marseglia A; Sonzogni A; Licini L; Nicastro E; D'Antiga L
    Hepatol Int; 2019 Jul; 13(4):510-518. PubMed ID: 31069759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
    Kocheise L; Piseddu I; Vonderlin J; Tjwa ET; Buescher G; Meunier L; Goeggelmann P; Fianchi F; Dumortier J; Riveiro Barciela M; Gevers TJG; Terziroli Beretta-Piccoli B; Londoño MC; Frankova S; Roesner T; Joerg V; Schmidt C; Glaser F; Sutter JP; Fründt TW; Lohse AW; Huber S; von Felden J; Sebode M; Schulze K
    Front Immunol; 2023; 14():1326078. PubMed ID: 38268921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.
    Liberal R; Grant CR; Holder BS; Cardone J; Martinez-Llordella M; Ma Y; Heneghan MA; Mieli-Vergani G; Vergani D; Longhi MS
    Hepatology; 2015 Sep; 62(3):863-75. PubMed ID: 25953611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis.
    Oo YH; Ackrill S; Cole R; Jenkins L; Anderson P; Jeffery HC; Jones N; Jeffery LE; Lutz P; Wawman RE; Athwal AK; Thompson J; Gray J; Guo K; Barton D; Hirschfield GM; Wong T; Guest P; Adams DH
    JHEP Rep; 2019 Oct; 1(4):286-296. PubMed ID: 32039380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of the possible impact of hepatitis viruses on the development and course of autoimmune liver diseases].
    Sbikina ES; Vinnitskaya EV; Batskikh SN; Sandler YG; Saliev KG; Khaimenova TY; Bordin DS
    Ter Arkh; 2023 Mar; 95(2):173-178. PubMed ID: 37167134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of autoimmune liver diseases - Understanding pathogenesis and improving morbidity and mortality.
    Engel B; Taubert R; Jaeckel E; Manns MP
    Liver Int; 2020 Feb; 40 Suppl 1():149-153. PubMed ID: 32077605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autoimmune liver diseases and their overlap syndromes].
    Strassburg CP
    Praxis (Bern 1994); 2006 Sep; 95(36):1363-81. PubMed ID: 16989180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases.
    Zhang H; Bernuzzi F; Lleo A; Ma X; Invernizzi P
    Mediators Inflamm; 2015; 2015():436450. PubMed ID: 26146463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude.
    Webb GJ; Ryan RP; Marshall TP; Hirschfield GM
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2587-2596. PubMed ID: 33493696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Herkel J
    Dig Dis; 2015; 33 Suppl 2():70-4. PubMed ID: 26642346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of gut microbiota in autoimmune liver diseases.
    Qian Q; He W; Tang R; Ma X
    Minerva Gastroenterol (Torino); 2023 Mar; 69(1):95-106. PubMed ID: 33793160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood.
    Maggiore G; Riva S; Sciveres M
    Minerva Gastroenterol Dietol; 2009 Mar; 55(1):53-70. PubMed ID: 19212308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling.
    Schwinge D; von Haxthausen F; Quaas A; Carambia A; Otto B; Glaser F; Höh B; Thiele N; Schoknecht T; Huber S; Steffens N; Lohse AW; Herkel J; Schramm C
    J Hepatol; 2017 Apr; 66(4):798-805. PubMed ID: 27965154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells.
    Liaskou E; Patel SR; Webb G; Bagkou Dimakou D; Akiror S; Krishna M; Mells G; Jones DE; Bowman SJ; Barone F; Fisher BA; Hirschfield GM
    J Autoimmun; 2018 Nov; 94():143-155. PubMed ID: 30119881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of complement activation in autoimmune liver disease.
    Biewenga M; Farina Sarasqueta A; Tushuizen ME; de Jonge-Muller ESM; van Hoek B; Trouw LA
    Autoimmun Rev; 2020 Jun; 19(6):102534. PubMed ID: 32234403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune liver disease, autoimmunity and liver transplantation.
    Carbone M; Neuberger JM
    J Hepatol; 2014 Jan; 60(1):210-23. PubMed ID: 24084655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges.
    He C; Yang Y; Zheng K; Chen Y; Liu S; Li Y; Han Q; Zhao RC; Wang L; Zhang F
    Ther Adv Chronic Dis; 2021; 12():2040622321993442. PubMed ID: 33633826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.